share_log

Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89

Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89

Canaccord Genuity开始覆盖Apogee Therapeutics,并给予买入评级,宣布目标股价为89美元
Benzinga ·  11/25 06:21  · 评级/大行评级

Canaccord Genuity analyst Edward Nash initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $89.

Canaccord Genuity 分析师爱德华·纳什开始对Apogee Therapeutics(纳斯达克:APGE)进行评级,给予买入评级,并宣布目标价为89美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发